HI
RETA

HBK Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HBK Investments’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,500
Closed -$897K – 1122
2019
Q1 		$897K Sell
10,500
-642
-6% -$53.3K 0.01% 701
2018
Q4 		$625K Sell
11,142
-3,158
-22% -$193K 0.01% 832
2018
Q3 		$1.17M Buy
+14,300
New +$1.01M 0.01% 673

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments's RETA Position: Q2 2019 in Review

HBK Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2019, closing a stake of 10,500 shares — an estimated $897K sold.

HBK Investments first reported a position in RETA in Q3 2018 and held it in 3 quarters. The position peaked at $1.17M in Q3 2018. 158 funds tracked by Wall St. Rank hold RETA as of Q2 2019.

  • HBK Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2019 after selling out during the quarter.
  • HBK Investments sold 10,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2019, an estimated $897K.
  • HBK Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 3 quarters.
  • HBK Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.17M in Q3 2018.
  • 158 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.